WO2002046208A3 - Method of producing biospecific molecules by protein trans-splicing - Google Patents

Method of producing biospecific molecules by protein trans-splicing Download PDF

Info

Publication number
WO2002046208A3
WO2002046208A3 PCT/US2001/045653 US0145653W WO0246208A3 WO 2002046208 A3 WO2002046208 A3 WO 2002046208A3 US 0145653 W US0145653 W US 0145653W WO 0246208 A3 WO0246208 A3 WO 0246208A3
Authority
WO
WIPO (PCT)
Prior art keywords
splicing
protein trans
bispecific molecules
molecules
antigen recognition
Prior art date
Application number
PCT/US2001/045653
Other languages
French (fr)
Other versions
WO2002046208A2 (en
Inventor
Jeff Himawan
Original Assignee
Elusys Therapeutics Inc
Jeff Himawan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elusys Therapeutics Inc, Jeff Himawan filed Critical Elusys Therapeutics Inc
Priority to JP2002547945A priority Critical patent/JP2004515233A/en
Priority to CA002427820A priority patent/CA2427820A1/en
Priority to AU2002241556A priority patent/AU2002241556B2/en
Priority to US10/415,840 priority patent/US7405276B2/en
Priority to EP01988231A priority patent/EP1339427A4/en
Priority to AU4155602A priority patent/AU4155602A/en
Publication of WO2002046208A2 publication Critical patent/WO2002046208A2/en
Publication of WO2002046208A3 publication Critical patent/WO2002046208A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain

Abstract

The invention provides methods of using protein trans-splicing for the production of bispecific molecule which has a first antigen recognition portion that binds a C3b-like receptor and a second antigen recognition portion that binds an antigenic molecule present in the circulatory system of a mammal. The invention also provides bispecific molecules produced by protein trans-splicing. The bispecific molecules of the invention can be used for the clearance of pathogenic antigenic molecules from the circulatory system of a mammal. The invention further provides methods of using protein trans-splicing for the production of poylclonal libraries of bispecific molecules, which comprise populations of bispecific molecules with different antigen recognition specificities. Such polyclonal libraries of bispecific molecules can be used for targeting multiple epitopes of a pathogenic antigenic molecule and/or multiple variants of a pathogenic antigenic molecule.
PCT/US2001/045653 2000-11-01 2001-11-01 Method of producing biospecific molecules by protein trans-splicing WO2002046208A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2002547945A JP2004515233A (en) 2000-11-01 2001-11-01 Method for producing bispecific molecules by protein trans-splicing
CA002427820A CA2427820A1 (en) 2000-11-01 2001-11-01 Method of producing biospecific molecules by protein trans-splicing
AU2002241556A AU2002241556B2 (en) 2000-11-01 2001-11-01 Method of producing bispecific molecules by protein trans-splicing
US10/415,840 US7405276B2 (en) 2000-11-01 2001-11-01 Method of producing bispecific molecules by protein trans-splicing
EP01988231A EP1339427A4 (en) 2000-11-01 2001-11-01 Method of producing biospecific molecules by protein trans-splicing
AU4155602A AU4155602A (en) 2000-11-01 2001-11-01 Method of producing biospecific molecules by protein trans-splicing

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24481100P 2000-11-01 2000-11-01
US60/244,811 2000-11-01

Publications (2)

Publication Number Publication Date
WO2002046208A2 WO2002046208A2 (en) 2002-06-13
WO2002046208A3 true WO2002046208A3 (en) 2002-08-08

Family

ID=22924197

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/045653 WO2002046208A2 (en) 2000-11-01 2001-11-01 Method of producing biospecific molecules by protein trans-splicing

Country Status (6)

Country Link
US (1) US7405276B2 (en)
EP (1) EP1339427A4 (en)
JP (1) JP2004515233A (en)
AU (2) AU2002241556B2 (en)
CA (1) CA2427820A1 (en)
WO (1) WO2002046208A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101422614A (en) 1999-11-28 2009-05-06 拉卓拉药物公司 Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof
AU5720601A (en) * 2000-04-26 2001-11-07 Elusys Therapeutics Inc Bispecific molecules and uses thereof
CA2435972C (en) * 2001-01-26 2011-09-13 University Of Lausanne Matrix attachment regions and methods for use thereof
EP1379277A4 (en) * 2001-03-15 2008-09-17 Elusys Therapeutics Inc Polyclonal populations of bispecific molecules and methods of production and uses thereof
JP2005539067A (en) * 2002-09-16 2005-12-22 エリューシス セラピューティクス，インコーポレーテッド Production of bispecific molecules using polyethylene glycol linkers
JP2007530438A (en) * 2003-03-28 2007-11-01 ジェフ ヒマワン， Anti-CR1 antibodies and compositions with reduced immunogenicity and therapeutic methods based thereon
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
PT2298347E (en) 2003-05-06 2016-01-29 Biogen Hemophilia Inc Clotting factor chimeric proteins for treatment of a hemostatic disorder
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
AU2004256021A1 (en) 2003-05-09 2005-01-20 University Of Massachusetts Non-human animals expressing heterologous complement receptor type 1 (CR1) molecules on erythrocytes and uses therefor
AU2004270103B2 (en) 2003-05-21 2012-02-23 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies against Bacillusanthracis protective antigen
US7700334B2 (en) 2003-08-12 2010-04-20 Lawrence Livermore National Security, Llc Photoswitchable method for the ordered attachment of proteins to surfaces
IN2014DN02483A (en) 2003-10-24 2015-05-15 Selexis Sa
US9493538B2 (en) * 2004-05-28 2016-11-15 University Of Massachusetts Snares for pathogenic or infectious agents and uses related thereto
UA94922C2 (en) 2005-11-07 2011-06-25 Зе Скріпс Рісьорч Інстітьют Method for controlling tissue factor signaling specificity in a mammalian subject, method for identifying an agent which specifically inhibits tissue factor signaling
EP1811031A1 (en) * 2006-01-18 2007-07-25 Millegen Method for selecting a peptide or polypeptide which binds to a target molecule
AU2007259329A1 (en) * 2006-05-12 2007-12-21 Farris, Darise Anthrax compositions and methods of use and production
CN103261222B (en) 2010-09-10 2017-07-28 医疗免疫有限公司 Antibody derivatives
AU2012314355B2 (en) 2011-09-28 2018-01-18 Zera Intein Protein Solutions, S.L. Split inteins and uses thereof
EP2877490B1 (en) 2012-06-27 2018-09-05 The Trustees of Princeton University Split inteins, conjugates and uses thereof
EP2777714A1 (en) * 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
BR112017013661B1 (en) 2014-12-23 2023-12-19 Nbe-Therapeutics Ag DRUG-BINDING PROTEIN CONJUGATE AND PHARMACEUTICAL COMPOSITION
CN106397599B (en) * 2016-02-23 2020-08-07 上海交通大学 Expression and preparation method of bivalent and bispecific antibody hybrid protein
CN106397598B (en) * 2016-02-23 2020-07-14 上海交通大学 Expression and preparation method of multivalent multispecific antibody and immune hybrid protein
US20220282231A1 (en) * 2018-09-30 2022-09-08 Shanghai Jiao Tong University Polypeptide composition
KR102129377B1 (en) * 2019-02-21 2020-07-02 성균관대학교산학협력단 An inductive plasmid display system for selecting a plasmid encoding a protein with specific properties expressed
US20230090778A1 (en) * 2020-02-07 2023-03-23 The Children's Medical Center Corporation Large gene vectors and delivery and uses thereof
JP2023545057A (en) * 2020-10-07 2023-10-26 ドレン バイオ， インコーポレイテッド Anti-Dectin-1 antibody and its use
CN115028741A (en) * 2022-06-21 2022-09-09 苏州工业园区唯可达生物科技有限公司 Tumor antigen-antibody complex, preparation method and application thereof
CN114989311A (en) * 2022-06-21 2022-09-02 苏州工业园区唯可达生物科技有限公司 3G9-LNM antibody coupling protein and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054312A (en) * 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2444713A1 (en) 1978-12-18 1980-07-18 Pasteur Institut PROCESS FOR PRODUCING DNA COMPRISING THE GENOME OF HEPATITIS B VIRUS AND VECTOR COMPRISING SAME
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimera monoclonal antibody and its preparation
US4672044A (en) 1984-08-24 1987-06-09 Scripps Clinic & Research Foundation Murine monoclonal antibody combining site to human C3b receptor (CR1)
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
AU606320B2 (en) 1985-11-01 1991-02-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP2938569B2 (en) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド Method for producing xenogeneic immunoglobulin and transgenic mouse
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5843440A (en) 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
AU8869291A (en) * 1990-10-04 1992-04-28 University Of Virginia Alumni Patents Foundation, The Primate erythrocyte bound monoclonal antibody heteropolymers
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ATE439435T1 (en) 1991-03-01 2009-08-15 Dyax Corp CHIMERIC PROTEIN COMPRISING MICROPROTEIN HAVING TWO OR MORE DISULFIDE BONDS AND FORMATIONS THEREOF
JP3672306B2 (en) 1991-04-10 2005-07-20 ザ スクリップス リサーチ インスティテュート Heterodimeric receptor library using phagemids
DE69233254T2 (en) * 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanized Heregulin antibody
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for screening antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
US5514778A (en) 1993-07-01 1996-05-07 Eli Lilly And Company Anti-picornaviral agents
AU696964B2 (en) 1994-02-28 1998-09-24 University Of Virginia Patent Foundation Antigen-based heteropolymers and method for treating autoimmune diseases using the same
US5653979A (en) 1995-03-30 1997-08-05 Trustees Of The University Of Pennsylvania Immunotargeting of plasminogen activators to the pulmonary endothelium
US5914112A (en) 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
CA2330471A1 (en) 1998-05-21 1999-11-25 The Trustees Of The University Of Pennsylvania Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots
US7041287B2 (en) 1998-05-21 2006-05-09 Trustees Of The University Of Pennsylvania Compositions and methods for selective dissolution of nascent intravascular blood clots

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054312A (en) * 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
MCGUINNESS, B.T.J. ET AL.: "Phage diabody repertoires for selection of large numbers of bispecific antibody fragments", NATURE GENETICS, vol. 14, 1996, pages 1149 - 1154, XP002100039 *
NOREN, C.J. ET AL.: "Dissecting the chemistry of protein splicing and its applications", ANGEW. CHEM. INT. ED., vol. 39, 2000, pages 451 - 466, XP002950975 *
PERLER, F.B.: "A natural example of protein trans-splicing", TRENDS BIOCHEM. SCI., vol. 24, 1999, pages 209 - 211, XP004170188 *
PLUECKTHUN ET AL.: "New protein engineering approaches to multivalent and bispecific antibody fragment", vol. 3, 1997, pages 83 - 105, XP002950976 *
SCOTT, P.C. ET AL.: "Production of cyclic peptides and proteins in vivo", PROC. NATL. ACAD. SCI. USA, vol. 96, 1999, pages 13638 - 13643, XP002137479 *

Also Published As

Publication number Publication date
EP1339427A4 (en) 2004-09-15
CA2427820A1 (en) 2002-06-13
WO2002046208A2 (en) 2002-06-13
JP2004515233A (en) 2004-05-27
US7405276B2 (en) 2008-07-29
US20040077842A1 (en) 2004-04-22
AU4155602A (en) 2002-06-18
EP1339427A2 (en) 2003-09-03
AU2002241556B2 (en) 2007-07-19

Similar Documents

Publication Publication Date Title
WO2002046208A3 (en) Method of producing biospecific molecules by protein trans-splicing
WO2003029458A3 (en) Method for producing protein libraries and for selecting proteins from said libraries
WO2002085945A3 (en) Vhh single heavy chain antibody and a method for its preparation in a mammal
WO2008054517A3 (en) Immunosuppressant binding antibodies and methods of obtaining and using same
MXPA02007756A (en) Antibodies that bind human interleukin 18 and methods of making and using.
WO2005035575A3 (en) Humanization of antibodies
EP2684889A3 (en) Multivariable antigens complexed with targeting humanized monoclonal antibody
ATE439380T1 (en) METHODS FOR PRODUCING HUMAN MONOCLONAL ANTIBODIES
WO2006002438A3 (en) Human monoclonal antibodies to fc gamma receptor i (cd64)
EP2186884A3 (en) HCV-anti-core monoclonal antibody
WO2005069970A3 (en) Antibody specificity transfer using minimal essential binding determinants
GB2383331A (en) Monoclonal antibody DS6 Tumor-associated antigen CA6 and methods of use thereof
AU2003259718A1 (en) Methods for humanizing rabbit monoclonal antibodies
WO2006031653A3 (en) Humanized anti-5t4 antibodies and anti-5t4 antibody / calicheamicin conjugates
EP3202786A3 (en) Sequence based engineering and optimization of single chain antibodies
EP1378525A3 (en) Humanized antibodies that bind to the antigen bound by antibody NR-LU-13 and their use in pretargeting methods
WO2004020579A3 (en) Method of humanizing immune system molecules
WO2007063415A3 (en) Methods of producing stable b-lymphocytes
WO2004025248A3 (en) Antibody pair screening methods
WO2004099242A3 (en) Streptococcus agalactiae antigens i + ii
WO2005028510A3 (en) Methods, kits, and compositions for the development and use of monoclonal antibodies specific to antigens of low immunogenicity
WO2002036738A3 (en) Affinity maturation by competitive selection
CA2348026A1 (en) Antibodies against semp1, methods for their production and uses thereof
WO2003048730A3 (en) Identification of high affinity molecules by limited dilution screening
WO2005051999A3 (en) Substance binding human igg fc receptor iib

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2427820

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002241556

Country of ref document: AU

Ref document number: 2002547945

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001988231

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001988231

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10415840

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2002241556

Country of ref document: AU